Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Furthermore we found up regulated protein and mRNA levels
2024-12-26

Furthermore, we found up-regulated protein and mRNA levels of adenosine kinase in mouse retina with TON. The up-regulation of ADK was previously demonstrated in diabetic retinopathy (Pang et al., 2010). Greater levels of ADK in activated macrophages and microglial cells abrogate the immune response.
-
br Acknowledgements This work was supported
2024-12-26

Acknowledgements This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) FINEP research grant “Rede Instituto Brasil
-
The cytoplasmic domain of muscle AChR is
2024-12-26

The cytoplasmic domain of muscle AChR is not accessible to iib iiia inhibitors in vivo. Theoretically, therapy with the cytoplasmic domains should be safe. Safety is demonstrated by the facts that: (1) rats repeatedly immunized with the cytoplasmic domains in TiterMax adjuvant do not develop EAMG,
-
In this study we make the first simultaneous recordings of
2024-12-26

In this study, we make the first simultaneous recordings of er tracker green release in multiple brain regions at a temporal resolution less than 1 s. One of the most striking findings is that acetylcholine release has a remarkably similar temporal profile in the mPFC and dHPC, suggesting a coordin
-
Although effects of low concentrations of agonist
2024-12-26

Although effects of low concentrations of agonist were not as thoroughly documented for heteromeric receptors such as the major chemokine receptor α4β2 nAChR, a similar mechanism of action was described to explain the potentiation of these receptors with low concentrations of acetylcholine-esterase
-
Erlotinib Eicosanoids are locally acting signaling lipids th
2024-12-26

Eicosanoids are locally acting signaling lipids that are produced from C20 polyunsaturated fatty acids (PUFAs), including arachidonic Erlotinib (AA, C20:4), eicosapentaenoic acid (C20:5) and eicosatrienoic acid (C20:3) (Dennis and Norris, 2015; Funk, 2001; Stables and Gilroy, 2011). According to th
-
In young animals the HT A receptor antagonist
2024-12-26

In young animals, the 5-HT2A Conessine antagonist ketanserin, at relatively low concentrations, shifted 5-HT concentration-response curves rightward, suggesting a role for 5-HT2A receptors in mediating 5-HT-induced contractions of the ureter. The slopes of the ketanserin Schild plots for the antago
-
The synthesis of compounds in which the ethyl
2024-12-26

The synthesis of compounds in which the ethyl linker has been modified to the carbamate and urea derivatives , and is shown in . Thus the diamine was reacted with glycolic Methotrexate Dosage to give the alcohol followed by Mitsunobu reaction with phthalimide to give . Deprotection with hydrazi
-
Because of the formation of phosphoenzyme intermediates the
2024-12-26

Because of the formation of phosphoenzyme intermediates, the enzymatic dnmt of P-ATPases can be divided into steps that include a kinase activity, by which an aspartate residue on the enzyme is phosphorylated, and a phosphatase activity, by which the phosphoenzyme is dephosphorylated. Another commo
-
br Acknowledgements M M M is the William Dow Lovett
2024-12-26

Acknowledgements M.M.M. is the William Dow Lovett Professor of Neurology and is supported by grants from the Michael J. Fox Foundation for Parkinson's Research, the American Parkinson Disease Association, the New Jersey Health Foundation/Nicholson Foundation, and by the National Institutes of Hea
-
br Conclusions In summary KLA isolated
2024-12-26

Conclusions In summary, KLA isolated from K. senegalensis exerted the anti-inflammatory activity via inhibiting the activation of NF-κB, AP-1, AKT and upregulating p38 MAPK/Nrf2/HO-1 signaling in LPS-stimulated RAW 264.7 and BV-2 Broad-spectrum phosphatase inhibitor (Fig. 9). These properties pro
-
Some members from the AAAP
2024-12-25

Some members from the AAAP family, namely the AUX1 and the LAX proteins, transport auxin instead of amino acids [48]. While there is some structural relationship between IAA and Trp, the substrate recognition characteristics seem different for these proteins: the auxins do not have any amino group o
-
An important observation is that
2024-12-25

An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s
-
However for a molecular target to be useful in AD
2024-12-25

However, for a molecular target to be useful in AD, it must rescue behavioral as well as biochemical insults. In humans, AD memory impairments typically declare themselves initially as disruption of episodic memory and consolidation of new memories, eventually progressing to global cognitive decline
-
As mentioned above variation of the A ring
2024-12-25

As mentioned above, variation of the A-ring was undertaken in order to improve microsomal stability and kinase selectivity relative to Natural flavor compound (). 1-Imidazole-2-carboxamides with substitution at the 4-position (–) were mostly tolerated with 4-cyano-imidazole-2-carboxamide () having
15700 records 36/1047 page Previous Next First page 上5页 3637383940 下5页 Last page